Healthcare
Live Price
Offline$54.00
-2.32% today
1Y Change
+18.96%
Window
Jun 25, 2025 โ Jun 23, 2026
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bristol-Myers Squibb Co (BMY) is a Healthcare stock with a market cap of $116.28B. The stock last traded around $54.00 and up 19.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +178.7%, a dividend yield of 4.4%. What stands out right now is revenue -0.2%, EPS +178.7%, free cash flow -7.9% with operating margin 28.5% and ROIC 13.5%. The dividend matters to the case here, with a current yield around 4.4%. Valuation is more restrained than many high-expectation growth names at P/E 16.0 and price/sales 2.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.2% vs +7.6% peer median
Operating Margin
Above sector median
+28.5% vs +19.4% peer median
P/E
Below sector median
16.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on Apr 30, 2026 with an EPS surprise of +11.3%.
The operating picture looks softer than before
Revenue is at -0.2% and EPS is at +178.7%, with operating margin around 28.5%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.8% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 Apr 30, 2026 | +11.3% | -3.9% | -7.2% | -5.6% |
Q1 2026 Mar 27, 2026 | +74.3% | +2.0% | +1.3% | -1.3% |
Q1 2026 Mar 13, 2026 | +40.0% | +1.1% | -2.7% | -1.7% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BMY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BMY Max Drawdown
-13.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BMY and SPY.
Company Overview
Bristol-Myers Squibb Co
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.